INBRE: CLEMSON U: ENHANCEMENT OF BIOENGINEERING AT CLEMSON UNIVERSITY

这个子项目是利用资源的许多研究子项目之一。 由NIH/NCRR资助的中心拨款提供。对子项目的主要支持 子项目的首席调查员可能是由其他来源提供的， 包括美国国立卫生研究院的其他来源。为子项目列出的总成本可能 表示该子项目使用的中心基础设施的估计数量， 不是由NCRR赠款提供给次级项目或次级项目工作人员的直接资金。 克莱姆森生物工程转化研究计划的研究人员将通过与格林维尔医院系统(GHS)医生的密切互动来增强他们研究的临床适用性。从这些互动中产生的想法在实验室和/或生物杀死设施中进行评估，通过GHS临床试验计划转移到临床，并以最佳方式导致技术转移和孵化。克莱姆森生物工程公司和GHS血管外科公司的这种合作于2004年成立了CreatiVasc Medical，LLC。这家位于南卡罗来纳州格林维尔的医疗设备公司提供创新的血管技术，解决肾透析连接的普遍问题。在该计划中，通过临床协作获得信息的研究将有助于遏制和降低医疗成本，并提高医疗效率。该计划的预期成果是：1)技术开发，以改善医疗保健；技术许可，初创公司发展，创业精神；2)经济影响，专业劳动力培训，继续教育，商业化和创造就业机会，地区和全州增长；3)增加NIH R01研究基金，通过独特的设施和临床参与提供创新数据。该计划将作为SC INBRE网络中的唯一资源，作为转化型生物医学的模板。将在自然科学研究所网络的主持下开展三个项目。他们之所以被选中，是因为他们的临床适用性和NIH R01资助的潜在数据生成，以及在NIH资助的生物医学研究中整合代表不足的群体的具有挑战性的机会。这些项目由三名初级教员领导，他们作为研究人员、翻译和导师/榜样展示了出色的技能。 PI将担任项目总监。CU的INBRE活动将由克莱姆森大学路线图理事会和一个外部指导委员会密切监测。该计划的评估将由计划主任和PROSTER领导定期进行，以监测CBC研究人员(包括目标教师)的研究效率。成功的衡量标准将包括出版物、奖项、赠款提案提交和资金以及教育成果。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. Researchers in the Clemson's Bioengineering Translational Research Program will enhance the clinical applicability of their research through close interaction with Greenville Hospital System (GHS) physicians. Ideas that emerge from these interactions are evaluated in the laboratory and/or bioskills facilities, transferred to the clinic through the GHS clinical-trial program, and optimally will lead to technology transfer and incubation. Such a collaboration between Clemson bioengineering and GHS vascular surgery established CreatiVasc Medical, LLC, in 2004. The Greenville, SC, medical device company delivers innovative vascular technologies that address universal problems of kidney dialysis connectivity. In the program, research informed by clinical collaboration will contribute to containment and reduction of health care costs and improve health care effectiveness. Anticipated outcomes of the program are: 1) Technology development for improved health caretechnology licensing, start-up company development, entrepreneurship; 2) Economic impactspecialized workforce training, continuing education, commercialization and job creation, regional and state-wide growth; and 3) Increased NIH R01 research fundinginnovative data through unique facilities and clinical involvement. This program will serve as a unique resource in the SC INBRE network as a template for translational biomedical. Three projects will be conducted under the auspices of the SC INBRE network. They have been selected because of their clinical applicability and potential data generation for NIH R01 funding, and as challenging opportunities for the integration of under-represented groups in NIH funded biomedical research. These projects are led by three junior faculty members who have demonstrated outstanding skills as researchers, translators, and mentors/role models. The PI will serve as the Program Director. The INBRE activities at CU will be closely monitored by the Clemson University Road Map Council and an external steering committee. Assessment of the program will be performed periodically by the Program Director and Thrust Leaders to monitor research productivity among CBC researchers including target faculty. Measures of success will include publications, awards, grant proposal submission and funding, and educational outcomes.